Medicare AdvantageReimbursementMedium impact
MA00.058, Reimbursement of Surgical Pathology Services for Prostate Biopsy
Independence Blue Cross·MA · Urology, Pathology, Oncology·Claims & Billing
Effective date
Mar 2, 2026
We identified it
Jun 19, 2026
Summary
This is a new Medicare Advantage policy (MA00.058) establishing reimbursement guidelines for surgical pathology services related to prostate biopsies. The policy becomes effective March 2, 2026, and billing teams must implement new reimbursement protocols for pathology claims associated with prostate biopsy procedures.
Action Required
Before March 2, 2026: Billing team must review the full policy text at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=12&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#medicare-advantage-ma00-058-reimbursement-of-surgical-pathol to identify specific CPT/HCPCS codes for surgical pathology services related to prostate biopsies. Update billing system rules and claim submission guidelines to align with the new reimbursement parameters. Train billing staff on the new policy requirements. Ensure all prostate biopsy pathology claims submitted on or after the effective date comply with MA00.058 guidelines. Failure to comply may result in claim denials or recoupment.